logo

Axsome Therapeutics, Inc. (AXSM)



Trade AXSM now with
  Date
  Headline
1/22/2020 7:22:12 AM Axsome Completes Patient Randomization In STRIDE-1 Phase 3 Trial Of AXS-05
12/30/2019 6:16:08 AM Axsome Therapeutics Announces AXS-07 Meets Co-Primary And Key Secondary Endpoints In MOMENTUM Phase 3 Migraine Trial
12/19/2019 7:13:39 AM Axsome Therapeutics Prices Public Offering Of 2 Mln Shares At $87/Shr
12/17/2019 7:11:43 AM Axsome Therapeutics Says Elected For Addition To NASDAQ Biotechnology Index
12/16/2019 6:03:54 AM Axsome Therapeutics Says AXS-05 Met Primary Endpoint In GEMINI Phase 3 Trial
12/3/2019 6:10:25 AM Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint In CONCERT Phase 2 Trial In Narcolepsy
11/21/2019 7:22:20 AM Axsome Therapeutics To Host Investor R&D Call Focusing On AXS-07
10/21/2019 7:08:44 AM Axsome Therapeutics Completes Patient Enrollment In CONCERT Study
10/16/2019 7:07:17 AM Axsome Therapeutics Completes Patient Enrollment In GEMINI Phase 3 Trial Of AXS-05 In Major Depressive Disorder
10/2/2019 7:10:56 AM Axsome Therapeutics To Provide Update On Continued Progress At 2019 Cantor Global Healthcare Conference
9/5/2019 7:11:07 AM Axsome To Present Positive Results From Phase 1 Pharmacokinetic Trial Of AXS-07
6/7/2019 7:05:18 AM Axsome Therapeutics Provides Update On Continued Progress At Annual Stockholders’ Meeting
  
 
>